Abstract
Radiation-induced lung fibrosis (RILF) is a severe side effect of radiotherapy in lung cancer patients that presents as a progressive pulmonary injury combined with chronic inflammation and exaggerated organ repair. RILF is a major barrier to improving the cure rate and well-being of lung cancer patients because it limits the radiation dose that is required to effectively kill tumor cells and diminishes normal lung function. Although the exact mechanism is unclear, accumulating evidence suggests that various cells, cytokines and regulatory molecules are involved in the tissue reorganization and immune response modulation that occur in RILF. In this review, we will summarize the general symptoms, diagnostics, and current understanding of the cells and molecular factors that are linked to the signaling networks implicated in RILF. Potential approaches for the treatment of RILF will also be discussed. Elucidating the key molecular mediators that initiate and control the extent of RILF in response to therapeutic radiation may reveal additional targets for RILF treatment to significantly improve the efficacy of radiotherapy for lung cancer patients.
Keywords: Fibrosis, lung cancer, radiotherapy, side effects.
Current Drug Targets
Title:Molecular Mechanisms and Treatment of Radiation-Induced Lung Fibrosis
Volume: 14 Issue: 11
Author(s): Nian-Hua Ding, Jian Jian Li and Lun-Quan Sun
Affiliation:
Keywords: Fibrosis, lung cancer, radiotherapy, side effects.
Abstract: Radiation-induced lung fibrosis (RILF) is a severe side effect of radiotherapy in lung cancer patients that presents as a progressive pulmonary injury combined with chronic inflammation and exaggerated organ repair. RILF is a major barrier to improving the cure rate and well-being of lung cancer patients because it limits the radiation dose that is required to effectively kill tumor cells and diminishes normal lung function. Although the exact mechanism is unclear, accumulating evidence suggests that various cells, cytokines and regulatory molecules are involved in the tissue reorganization and immune response modulation that occur in RILF. In this review, we will summarize the general symptoms, diagnostics, and current understanding of the cells and molecular factors that are linked to the signaling networks implicated in RILF. Potential approaches for the treatment of RILF will also be discussed. Elucidating the key molecular mediators that initiate and control the extent of RILF in response to therapeutic radiation may reveal additional targets for RILF treatment to significantly improve the efficacy of radiotherapy for lung cancer patients.
Export Options
About this article
Cite this article as:
Ding Nian-Hua, Li Jian Jian and Sun Lun-Quan, Molecular Mechanisms and Treatment of Radiation-Induced Lung Fibrosis, Current Drug Targets 2013; 14 (11) . https://dx.doi.org/10.2174/13894501113149990198
DOI https://dx.doi.org/10.2174/13894501113149990198 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Individualized Treatment Planning in Oncology: Role of PET and Radiolabelled Anticancer Drugs in Predicting Tumour Resistance
Current Pharmaceutical Design Nanoparticle Delivery Systems for DNA/RNA and their Potential Applications in Nanomedicine
Current Topics in Medicinal Chemistry Recent Advances in Receptor-Targeted Fluorescent Probes for In Vivo Cancer Imaging
Current Medicinal Chemistry Scalarane Sesterterpenoids
Current Bioactive Compounds Non-coding RNAs in Lung Cancer Chemoresistance
Current Drug Metabolism Promising Anti-Fibrotic Approaches for Future Treatment of Systemic Sclerosis
Current Rheumatology Reviews Repurposing Pharmaceuticals as Neuroprotective Agents for Cerebral Malaria
Current Clinical Pharmacology The Protein Profile of Fibroblasts: The Role of Proteomics
Current Proteomics A New Strategy to Target Acute Myeloid Leukemia Stem and Progenitor Cells Using Chidamide, a Histone Deacetylase Inhibitor
Current Cancer Drug Targets PET Studies on P-Glycoprotein Function in the Blood-Brain Barrier: How it Affects Uptake and Binding of Drugs within the CNS
Current Pharmaceutical Design Current Methods and Research Progress in Nanomaterials Risk Assessment
Current Drug Metabolism Potential of DNMT and its Epigenetic Regulation for Lung Cancer Therapy
Current Genomics The PA207 Peptide Inhibitor of LIM-only Protein 2 (Lmo2) Targets Zinc Finger Domains in a Non-specific Manner
Protein & Peptide Letters Bypass Mechanisms of Resistance to Tyrosine Kinase Inhibition in Chronic Myelogenous Leukaemia
Current Drug Discovery Technologies The Role of Mitochondria in Cancer Induction, Progression and Changes in Metabolism
Mini-Reviews in Medicinal Chemistry Advances in the Systemic Treatment of Neuroendocrine Tumors in the Era of Molecular Therapy
Anti-Cancer Agents in Medicinal Chemistry Lipid Nanoparticles to Deliver miRNA in Cancer
Current Pharmaceutical Biotechnology Working Hypothesis: Elimination of Cancer Stem Cells in Solid Tumors by Immuno-Gene Therapy Using Cancer Vaccines and Created-Inhibitory RNA
Current Cancer Therapy Reviews Roles of Natural Compounds from Medicinal Plants in Cancer Treatment: Structure and Mode of Action at Molecular Level
Medicinal Chemistry Systems Biology Approaches to a Rational Drug Discovery Paradigm
Current Topics in Medicinal Chemistry